Yarbrough Capital’s Maravai LifeSciences MRVI Stock Holding History

Yarbrough Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,731	Closed	-$177K	–	206
2024 Q2	$177K	Hold	24,731	–	–	0.01%	196
2024 Q1	$214K	Hold	24,731	–	–	0.01%	194
2023 Q4	$162K	Hold	24,731	–	–	0.01%	200
2023 Q3	$247K	Hold	24,731	–	–	0.01%	193
2023 Q2	$307K	Hold	24,731	–	–	0.02%	178
2023 Q1	$346K	Buy	+24,731	New	+$355K	0.03%	167

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Yarbrough Capital's MRVI Position: Q3 2024 in Review

Yarbrough Capital sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 24,731 shares — an estimated $177K sold.

Yarbrough Capital first reported a position in MRVI in Q1 2023 and held it in 6 quarters. The position peaked at $346K in Q1 2023. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Yarbrough Capital reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Yarbrough Capital sold 24,731 Maravai LifeSciences shares in Q3 2024, an estimated $177K.
Yarbrough Capital first reported a position in Maravai LifeSciences in Q1 2023 and held it in 6 quarters.
Yarbrough Capital's Maravai LifeSciences position peaked at $346K in Q1 2023.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Yarbrough Capital's 13F filing for Q3 2024, filed 15 Oct 2024.